Displaying 2721 - 2740 of 4735
100th Anniversary Symposium
Dissenting Statement of Commissioner Maureen K. Ohlhausen - In the Matter of AmeriGas and Blue Rhino
FTC Requires Divestiture as a Condition of Surgery Center Holdings' Acquisition of Competitor Symbion
Blue Rhino, AmeriGas Settle FTC Charges of Restraining Competition
FTC Requests Public Comments on SCI’s Application to Approve Sale of Funeral Home in Auburn, California
FTC Requests Public Comments on Graco’s Application for Approval to Divest Liquid Finishing Business Assets to Carlisle Companies
Paglia, Ralph
More than 20 Current and Former FTC Officials Will Participate in Agency’s 100th Anniversary Symposium on Nov. 7
FTC Requests Public Comment on Community Health Systems’ Application to Approve Sale of Carolina Pines Regional Medical Center to Capella Healthcare, Inc.
FTC Approves SCI’s Applications to Divest Assets in California, Florida, and Tennessee
Federal Trade Commission Appoints Ashkan Soltani as Chief Technologist
FTC Approves Final Order Preserving Competition in the Market for Over-the-Counter Motion Sickness Drugs
Prestige Brands Holdings, Inc. and Insight Pharmaceuticals Corporation, In the Matter of
Pharmaceutical company Prestige Brands Holdings, Inc., the maker of Dramamine, agreed to divest assets and marketing rights for the over-the-counter motion sickness drug Bonine to settle FTC charges that Prestige’s proposed acquisition of Insight Pharmaceuticals Corporation would likely be anticompetitive. Prestige proposed to acquire Insight for $750 million. According to the FTC’s complaint, Prestige’s Dramamine, which is the best-selling branded product in the market for over-the-counter motion-sickness drugs, and Insight’s Bonine, are the only two branded products with significant sales. Absent a remedy, the acquisition would eliminate the close competition between Dramamine and Bonine, likely leading to higher prices for consumers.
FTC Approves Final Orders Requiring Two Professional Associations to Eliminate Rules that Restrict Competition among Their Members
National Association of Teachers of Singing, Inc., In the Matter of
The National Association of Teachers of Singing, Inc. (NATS) has agreed to eliminate provisions in its code of ethics that limit competition among its members. The FTC charged that NATS, which represents more than 7,300 vocal arts teachers in the United States, restrained competition in violation of the FTC Act through a code of ethics provision that prohibits members from soliciting students from other members. The order settling the FTC’s complaint against NATS requires that it stop restraining members from seeking teaching work, and stop telling its members that soliciting students is unethical. The order also requires NATS to obtain a certification from each of its chapters that the chapter is not restricting solicitation, advertising, or price-related competition by its members, and to sever its ties with any chapter that NATS learns is restraining solicitation, advertising, or price-related competition by its members. NATS also must implement an antitrust compliance program.
Displaying 2721 - 2740 of 4735